The expansion of advanced targeted therapies has changed the way patients with PsA are treated. However, despite the effectiveness of these therapies, many patients do not achieve optimal response to these therapies. Sex and gender are important factors that influence treatment response in PsA. Women with PsA are less likely to achieve remission, are more likely to experience side effects and tend to stop treatments earlier than men.

SAGE-PsA is an international, multicenter study supported by GRAPPA through multi-pharma supported grants. The aim of the study is to understand how sex and gender influence response to advanced therapies in PsA. The investigators hope to discover biological and socio-cultural mechanisms that explain the differences in treatment response between men and women with PsA. The results of this study will improve our understanding of the impact of sex and gender on PsA which will contribute to more personalized approach to care of people living with PsA.